Tetra Bio-Pharma Discusses Development of PPP003 Drug for Cytokine Reduction with The Stock Day Podcast

The Stock Day Podcast welcomed Tetra Bio-Pharma (TBPMF)(“the Company”), a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. CEO of the Company, Dr. Guy Chamberland, joined Stock Day host Everett Jolly.  FULL PRESS RELEASE: https://stockdaymedia.com/tetra-bio-pharma-discusses-development-of-ppp003-drug-for-cytokine-reduction-with-the-stock-day-podcast-tbpmf-may-7-2020/ Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy